Dividendos de Vertex Pharmaceuticals

Dividendo controles de criterios 0/6

Vertex Pharmaceuticals no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	US$14.00
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

Sep 19

Vertex wins FDA label expansion for cystic fibrosis drug to add younger children

Sep 02

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de VRTX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de VRTX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Vertex Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de VRTX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (VRTX)	n/a
Suelo de mercado 25% (US)	1.6%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (VRTX)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de VRTX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de VRTX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de VRTX para determinar si sus dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que VRTX no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Vertex Pharmaceuticals

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Executive VP & COO notifies of intention to sell stock

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Executive VP & CFO notifies of intention to sell stock

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Lead Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Now 20% undervalued after recent price drop

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 21% undervalued

Lead Independent Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Now 20% undervalued

Executive VP & COO notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Now 21% undervalued

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

CEO, President & Director notifies of intention to sell stock

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Executive VP & CFO notifies of intention to sell stock

Executive VP & CFO notifies of intention to sell stock

Insider notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Now 23% undervalued after recent price drop

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Independent Director exercised options and sold US$1.1m worth of stock

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Insider notifies of intention to sell stock

Insider exercised options and sold US$151k worth of stock

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference